Understanding how the IFNy pathway affects lung cancer and immune response
Deconvoluting the contributions of the IFNy pathway components to lung TME and tumor immunity
This study is looking at how a specific pathway in the immune system affects the growth of non-small cell lung cancer and how well patients respond to immunotherapy, using mice to see what happens when certain genes are turned off.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10994395 on NIH RePORTER |
What this research studies
This research investigates the role of the interferon gamma (IFNy) pathway in the tumor microenvironment of non-small cell lung cancer (NSCLC). By using advanced genomic techniques, the study aims to identify how different components of this pathway influence tumor immunity and patient responses to immunotherapy. The researchers will utilize a mouse model to knock out specific cytokine genes and observe the effects on tumor growth and immune cell infiltration. This approach seeks to clarify the complex interactions within the tumor environment that affect treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are considering or currently undergoing immunotherapy.
Not a fit: Patients with other types of lung cancer or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies for lung cancer patients, potentially enhancing their treatment responses and survival rates.
How similar studies have performed: Previous research has shown promising results in understanding immune checkpoint blockade therapies, but this specific approach to dissecting the IFNy pathway is relatively novel.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Tepper, Alexander — Icahn School of Medicine at Mount Sinai
- Study coordinator: Tepper, Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.